Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherapy in Animal Models
02 Luglio 2009 - 3:00PM
PR Newswire (US)
EAST SETAUKET, N.Y., July 2 /PRNewswire-FirstCall/ -- Lixte
Biotechnology Holdings (OTC:LIXT) (BULLETIN BOARD: LIXT) announced
today that investigators of the National Institute of Neurological
Disorders and Stroke (NINDS) and the National Cancer Institute
(NCI), National Institutes of Health and Lixte reported that its
novel compound, LB-1.2, enhances the effectiveness of two standard
chemotherapy drugs in mouse models of human cancers. This research
is being conducted under a Cooperative Research and Development
Agreement between NINDS and Lixte. The report was published online
in the early edition (June 29) of the Proceedings of the National
Academy of Science (US). The print version will appear July 14. Dr.
John S. Kovach, President and CEO of Lixte, said "LB-1.2 exerts
anti-cancer activity directly on the cancer cell and, more
dramatically, by preventing cancer cells from recovering from
DNA-damage produced by standard anti-cancer drugs. In mouse models,
LB-1.2 plus Temozolomide caused complete regression without
recurrence in 50 % of animals bearing tumors of human glioblastoma
multiforme (GBM), the most common and aggressive brain tumor of
adults, and also, marked regression of neuroblastoma, the most
common cancer of children. Temozolomide, the standard drug for the
treatment of patients with GBM, by itself caused regression but
with recurrence of all tumors." Dr. Kovach added "that, since
LB-1.2 has a biochemical action similar to an older drug used for
anticancer treatment for many years in China, we are cautiously
optimistic that LB-1.2 will be well tolerated by cancer patients
and hopefully, will potentially be as effective as it is in animal
models of human cancer. We believe that adding LB-1.2 may be a
general method for improving the effectiveness of several standard
anticancer drugs not only against tumors of the brain and neural
tissue but also against other cancers sensitive to drugs that work
by damaging DNA. Safety, of course, must be demonstrated first in
animal studies and subsequently in Phase I clinical trials before
evaluation of therapeutic effectiveness can be assessed against
different cancer types in patients." About Lixte Biotechnology
Holdings, Inc.: Lixte Biotechnology Holdings, Inc. is a cancer
therapeutics and diagnostics company. Founded as a
biomarker-diagnostics company in 2005, Lixte develops new
chemotherapy drugs targeting molecular abnormalities of common
human cancers. About the National Institute of Neurological
Disorders and Stroke (NINDS), (NIH): NINDS
(http://www.ninds.nih.gov/) is a component of the National
Institutes of Health (NIH), and is the nation's primary supporter
of biomedical research on the brain and nervous system. The
National Institutes of Health (NIH) -- The Nation's Medical
Research Agency -- includes 27 Institutes and Centers and is a
component of the U.S. Department of Health and Human Services. It
is the primary federal agency for conducting and supporting basic,
clinical and translational medical research, and it investigates
the causes, treatments, and cures for both common and rare
diseases. For more information about NIH and its programs, visit
http://www.nih.gov/. Forward-Looking Statements This announcement
contains certain forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, and Section 21E of the
Securities Exchange Act of 1934. For example, statements regarding
the Company's financial position, business strategy and other plans
and objectives for future operations, and assumptions and
predictions about future product demand, supply, manufacturing,
costs, marketing and pricing factors are all forward-looking
statements. These statements are generally accompanied by words
such as "intend," anticipate," "believe," "estimate,"
"potential(ly)," "continue," "forecast," "predict," "plan," "may,"
"will," "could," "would," "should," "expect" or the negative of
such terms or other comparable terminology. The Company believes
that the assumptions and expectations reflected in such
forward-looking statements are reasonable, based on information
available to it on the date hereof, but the Company cannot provide
assurances that these assumptions and expectations will prove to
have been correct or that the Company will take any action that the
Company may presently be planning. However, these forward-looking
statements are inherently subject to known and unknown risks and
uncertainties. Actual results or experience may differ materially
from those expected or anticipated in the forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, regulatory policies,
available cash, research results, competition from other similar
businesses, and market and general economic factors. This
discussion should be read in conjunction with the condensed
consolidated financial statements and notes thereto included on
Form 10-QSB for the quarter ending March 31, 2009. Please see our
Website: http://www.lixte.com/ For Investor Information, please
contact: Jane Trigg 631 830 7090 DATASOURCE: Lixte Biotechnology
Holdings CONTACT: Jane Trigg of Lixte Biotechnology Holdings,
+1-631-830-7090, Web Site: http://www.lixte.com/
Copyright